Active Recombinant Full Length Human SMAD1 Protein, GST-tagged

• Cat.No.: SMAD1-6690HF
• Product Overview: Full-length human Smad1 [1-465(end) amino acids of accession number NP_005891.1] was expressed as N-terminal GST-fusion protein (79 kDa) using E.coli expression system. GST-Smad1 was purified by using glutathione sepharose chromatography.

Specification

• Source: E. coli
• Species: Human
• Tag: GST
• Form: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5
• Bio-activity: The phosphorylational ability of the protein was determined by ELISA. The substrate protein was incubated with the indicated enzyme, and after stopping kinase reaction by EDTA, the reaction solution was transferred into glutathione-coated plate. Phosphorylation was detected by anti-phospho antibody and HRP-labeled anti-rabbit IgG
• Protein length: 1-465(end)
• Purity: 78%
• Applications: SDS-PAGE
• Storage: Store at -80C. Avoid repeating freeze-thaws.

Gene Information

• Gene Name: SMAD family member 1
• Official Symbol: SMAD1
• Synonyms: MADH1; MADR1; JV4-1
• Protein Refseq: NP_005891.1
• UniProt ID: Q15797

Reviews

06/08/2022

Whether I am investigating enzymatic activity, studying protein-protein interactions, or testing its role in signaling pathways, the SMAD1 protein consistently performs exceptionally well.

08/08/2021

This versatility allows me to explore different aspects of my research with confidence and accuracy.

05/02/2018

The SMAD1 protein's excellent functionality makes it highly suitable for various trial applications.

Q&As

What technologies are commonly used to study the expression and activity of SMAD1 in clinical research?

Techniques like Western blotting, immunohistochemistry, and qRT-PCR are commonly employed to study SMAD1 expression and activity in clinical research.

How might targeting SMAD1 have implications for anti-cancer therapies?

Modulating SMAD1 activity could be explored as a potential strategy for developing anti-cancer therapies, particularly in cancers where the TGF-β pathway is dysregulated.

Are there any known genetic mutations in the SMAD1 gene associated with human diseases?

Yes, mutations in the SMAD1 gene have been identified in certain individuals with congenital disorders and developmental abnormalities.

How does SMAD1 interact with other proteins in the TGF-β pathway?

SMAD1 forms complexes with other SMAD proteins, transducing signals from TGF-β receptors to the nucleus, where they regulate gene expression.

How can SMAD1 be targeted for therapeutic interventions in bone-related disorders?

Targeting SMAD1 or its downstream effectors in the TGF-β pathway may offer potential therapeutic strategies for bone-related disorders, such as osteoporosis.